来氟米特在IgA肾病中的研究进展

Progress of Leflunomide in IgA Nephropathy

来氟米特(LEF)是一种通过抑制嘧啶的从头合成,从而直接抑制淋巴细胞和B细胞增殖的免疫调剂剂,属异噁唑类衍生物,目前临床上常用于治疗成人类风湿性关节炎(RA)和狼疮性肾炎(LN)。目前有研究表明来氟米特可以作为新的辅助免疫调节剂有效地降低IgA肾病(IgAN)患者的蛋白尿。IgA肾病是一种具有特征性免疫病理表现、由多种临床和病理表型组成的一组临床–病理综合征。IgAN的临床表现、病理特征及预后存在高度异质性,目前对其病因和发病机制尚未有清晰的认识,因而没有统一的治疗方案。本文的目的是通过对LEF在IgAN中应用的相关研究进行综述,来探讨LEF在IgAN中所具有的有效性及安全性。

Leflunomide is an immunomodulator that directly inhibits the proliferation of lymphocytes and B cells by inhibiting the de novo synthesis of pyrimidine. It belongs to isoxazole derivatives and is currently commonly used in the treatment of adult rheumatoid arthritis (RA) and lupus nephritis (LN). At present, some studies have shown that leflunomide can effectively reduce proteinuria in patients with IgA nephropathy (IgAN) as a new adjuvant immune modulator. IgA nephropathy is a group of clinical pathological syndromes with characteristic immunopathological manifestations and composed of a variety of clinical and pathological phenotypes. The clinical manifestations, pathological features and prognosis of IgAN are highly heterogeneous. At present, there is no clear understanding of its etiology and pathogenesis, so there is no unified treatment scheme. The purpose of this paper is to discuss the efficacy and safety of leflunomide (LEF) in IgAN by reviewing the relevant studies on the application of leflunomide (LEF) in IgAN.